Upgrade to SI Premium - Free Trial

H.C. Wainwright Reiterates Buy Rating on Rani Therapeutics Holdsing s (RANI)

October 18, 2024 6:46 AM
H.C. Wainwright analyst Mitchell S. Kapoor reiterated a Buy rating and $9.00 price target on Rani Therapeutics Holdsing s (NASDAQ ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments